Other

Phase 2Small molecule

AstraZeneca

Other is one of 181 small molecule programs targeting Immunodeficiency Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

180

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immunodeficiency DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Lung DiseaseActive, not recruiting

Motion SicknessActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

PsoriasisActive, not recruiting

Dilated CardiomyopathyActive, not recruiting

Immunodeficiency DiseasePreclinical

Active, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Lung DiseasePreclinical

Active, not recruiting

Motion SicknessPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

PsoriasisPreclinical

Active, not recruiting

Dilated CardiomyopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Other

AstraZeneca

Phase 2

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Remeron

OOrganon and Co

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Motion Sickness

NCT05852730

N/ARecruiting

Dilated Cardiomyopathy

NCT06091475

Q4 2029

Phase 2Not yet recruiting

Treatment

NCT06692491

Clinical

Trials by Indication[1]

Dilated Cardiomyopathy1 trial

Therapy to Maintain Remission in Dilated Cardiomyopathy

Recruiting·IImperial College London·N/A·NCT06091475·50 enrolled

Immunodeficiency Disease1 trial

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

Unknown status·AADMA Biologics, Inc.··NCT03037359·200 enrolled

Lung Disease1 trial

Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases

Unknown status·KKU Leuven··NCT02488590·180 enrolled

EGFR Mutation1 trial

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Completed· AstraZeneca logo

AstraZeneca··NCT03137264·44 enrolled

Treatment1 trial

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

4 more indications

Psoriasis1 trial

PSOREAL - Managing PSOriasis in the REAL World

Completed· LEO Pharma logo

LEO Pharma··NCT02935582·1,214 enrolled

Motion Sickness1 trial

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Recruiting·RRepurposed Therapeutics, Inc.·Phase 2·NCT05852730·80 enrolled

Type 2 Diabetes Mellitus1 trial

Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT04744636·100 enrolled

Non-Small Cell Lung Cancer1 trial

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Terminated·IInventisBio Co., Ltd·Phase 1/2·NCT05492045·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Other. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Other compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Other. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Other

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2029

Trials by Indication[1]

Dilated Cardiomyopathy1 trial

Immunodeficiency Disease1 trial

Lung Disease1 trial

EGFR Mutation1 trial

Treatment1 trial

Psoriasis1 trial

Motion Sickness1 trial

Type 2 Diabetes Mellitus1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News